Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma

  • Technology appraisal guidance
  • TA720
  • Published: 
Download guidance (PDF)

2 Information about chlormethine gel

Marketing authorisation indication

2.1 Chlormethine gel (Ledaga, Recordati Rare Diseases and Helsinn Healthcare) is indicated for 'the topical treatment of mycosis fungoides-type cutaneous T‑cell lymphoma (MF‑type CTCL) in adult patients'.

Dosing in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price for chlormethine gel is £1,000 per 60 g tube (excluding VAT; BNF online accessed 17 July 2020).

2.4 The company has a commercial arrangement. This makes chlormethine gel available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.